Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

EstoniaBack to Estonia

Clinical trials in Tartu – page 5

144 clinical trials in Tartu, Estonia across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

EstoniaOur site in EstoniaKliinilisedUuringud.ee(opens in a new tab)
Tartu at a glance
144
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

144 trials in Tartu

Open in trial search

Primary biliary cholangitis

Not yet recruiting

Safety and Efficacy of Saroglitazar Magnesium in Patients with Primary Biliary Cholangitis: A Long‑Term Randomized Placebo‑Controlled Study

Investigational
Countries:EstoniaEstonia
  • Participants:18–64 years
  • Substances:Saroglitazar hemimagnesium
  • Sponsor:Zydus Therapeutics Inc.

Prostate cancer

Not yet recruiting

Study of vinorelbine and cisplatin with radiation therapy for patients with castration- and taxane-resistant prostate cancer

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Tartu University Hospital

Osteoarthritis

Not yet recruiting

Study on the Use of Autologous Adipose Tissue-Derived Stromal Vascular Fraction for Patients with Advanced Temporomandibular Joint Osteoarthritis

InvestigationalNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years
  • Substances:Autologous Adipose Tissue-Derived Stromal Vascular Fraction
  • Sponsor:Tartu University Hospital

Colitis ulcerative

Not yet recruiting

Study on the Safety and Effectiveness of Lutikizumab and Adalimumab for Adults with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Diffuse large B-cell lymphoma refractory

Not yet recruiting

Study Comparing R-MINI-CHOP and R-MINI-CHP with Polatuzumab Vedotin for Treating Diffuse Large B-Cell Lymphoma in Patients Aged 80 and Older or Frail Patients Aged 75 and Older

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Region Skane

Arteriosclerosis

Not recruiting

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Dermatitis atopic

Not recruiting

Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Investigational
Countries:EstoniaEstonia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Dermatitis atopic

Not recruiting

Study on Rocatinlimab for Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Pneumococcal immunisation

Not recruiting

Study on the Safety and Immune Response of a 21-Valent Pneumococcal Vaccine in Healthy Infants, Toddlers, Children, and Adolescents

InvestigationalNo placebo
Countries:EstoniaEstonia
  • Participants:0–17 years · Healthy volunteers
  • Substances:Pneumococcal polysaccharide serotype 1
  • Sponsor:Sanofi Pasteur Inc.

Respiratory syncytial virus infection+3

Not recruiting

Study on the Immune Response and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:GlaxoSmithKline Biologicals

Psoriasis

Not recruiting

Study on Long-term Safety and Effectiveness of ESK-001 for Patients with Moderate to Severe Plaque Psoriasis

Investigational
Countries:EstoniaEstonia
  • Participants:18–64 years · 65+ years
  • Substances:Envudeucitinib
  • Sponsor:Alumis Inc.

Other cities in Estonia

The busiest research cities in the country

All 11 cities in Estonia

Clinical research in Tartu

What the registry says about research in the country

01 Autoimmune Conditions

Several trials focusing on innovative treatments for autoimmune disorders, particularly investigating new therapies for psoriatic arthritis and plaque psoriasis. Research includes testing of novel compounds like zasocitinib and evaluating long-term safety profiles.

  • Psoriatic Arthritis
  • Plaque Psoriasis
  • Sjögren's Syndrome

Studies aim to improve disease management and patient outcomes through targeted therapies.

02 Oncology Research

Comprehensive cancer research programs examining treatments for various types of lung cancer and other malignancies. Studies focus on combination therapies and novel treatment approaches.

  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer
  • Bladder Cancer
  • Glioblastoma

Emphasis on immunotherapy combinations and targeted treatments for better patient outcomes.

03 Metabolic and Bone Disorders

Investigation of treatments for osteoporosis and related conditions, with a focus on postmenopausal women and innovative therapeutic approaches.

  • Postmenopausal Osteoporosis
  • Bone Density Management
  • Primary Biliary Cholangitis

Research aims to improve bone health and manage metabolic conditions through new therapeutic options.

Back to EstoniaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.